Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

nuing operations (36,660) (29,556) (78,672) (58,749) Discontinued operations: Income (loss) from discontinued operations - (4) - 74 --- -- --- -- Net loss $(36,660) $(29,560) $(78,672) $(58,675) ======== ======== ======== ======== Basic and diluted loss per share: Continuing operations $(0.81) $(0.76) $(1.83) $(1.51) Discontinued operations - - - - --- --- --- --- Net loss per share $(0.81) $(0.76) $(1.83) $(1.51) ====== ====== ====== ====== Shares used in computing basic and diluted net loss per share 45,023 38,956 42,986 38,915 ====== ====== ====== ====== * As adjusted due to the implementation of FSP APB 14-1 "Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)" InterMune, Inc. PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) June 30, December 31, 2009 2008* ---- ---- Cash, cash equivalents and available-for-sale securities $145,534 $154,713 Other assets 20,113 17,097 ------ ------ Total
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Second generation biofuels are a viable solution ... However, as natural gas is very cheap, this is affecting ... as valuable as they could be in comparison to natural ... has made it difficult for renewable energy developers to get ... ground. For these reasons, certain companies have shifted their focused ...
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today a ... to provide access to Nanosyn,s microfluidics screening and ... for novel small molecule therapeutics. ... work with FORMA Therapeutics to explore key pathways ... FORMA Therapeutics, decision to work with us is ...
(Date:7/29/2014)... July 29, 2014  ImmunoClin Corporation (IMCL) is ... treatment of infectious diseases as well as nutraceuticals. ... prevention of pathologies like cardiovascular disease, Alzheimer,s disease ... ImmunoClin Corporation will complete the strategic relocation of ... , a key center of North American ...
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready ... The Innovation Center @3401 , a collaborative effort of ... Center to help attract and nurture start-up businesses in ... , The Innovation Center @3401 (ic@3401), which ... is the new home of DreamIt Ventures and ...
Breaking Biology Technology:Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3
... (Nasdaq: GENZ ) and Sunway Biotech Co. ... develop, and commercialize the,experimental gene therapy Ad2/HIF-1a in ... candidate and is currently in Phase 2 clinical,testing ... is a privately-held, Shanghai-based biotechnology company,founded in 1995. ...
... 25 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ) ... Japanese Pharmaceuticals and Medical,Devices Agency for the treatment ... a milestone payment plus royalties from Kirin,Pharma, a ... market the,drug in Japan. Kirin licensed cinacalcet from ...
... Inc. (Nasdaq:,ZGEN) announced today that it will report ... 2007. Members of the company,s senior,management will discuss ... a conference call and webcast on Wednesday, October ... ZymoGenetics Q3 2007 Financial Results Conference Call may ...
Cached Biology Technology:Genzyme and Sunway to Collaborate on Gene Therapy Program in China 2Genzyme and Sunway to Collaborate on Gene Therapy Program in China 3Genzyme and Sunway to Collaborate on Gene Therapy Program in China 4NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in Japan 2ZymoGenetics to Host Conference Call and Webcast on October 31, 2007 to Discuss Third Quarter Results 2
(Date:7/29/2014)... -- Research and Markets  has announced the addition ... 2014-2018" report to their offering. ... BI refers to applications and technologies that are used ... a company,s operations. BI help organizations to acquire comprehensive ... metrics on sales, production, and internal operations. ...
(Date:7/29/2014)... But on the remote UK overseas territory of Ascension ... is undergoing something of a renaissance. , Writing in ... the University of Exeter and Ascension Island Government Conservation ... at the remote South Atlantic outpost has increased by ... the 1970s. As many as 24,000 nests are now ...
(Date:7/29/2014)... (UM SOD) and Medicine (UM SOM) jointly announced ... million grant award from the National Institute of ... Institutes of Health to study the causes, prevention ... which renews a previous $12 million five-year NIAID-funded ... research by studying chlamydial and gonorrheal diseases as ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4
... cousin of the bacterium that debilitated thousands of World War ... who had been on an international vacation. The woman, who ... typhoid fever, two infections that can occur in returning travelers. ... was infected with a new bacterium that had never before ...
... a single protein with an experimental drug prevented and ... mice that had been fed unhealthy diets and were ... article published online at Nature on June 6, 2007. ... chair of the Department of Genetics and Complex Diseases ...
... new clues to a very cold case: the disappearance of ... all Ice Age giants, according to a June 7th report ... , DNA lifted from the bones, teeth, and tusks of ... expansion after the last interglacial period. After the mammoths’ migration, ...
Cached Biology News:New bacterium discovered -- related to cause of trench fever 2New bacterium discovered -- related to cause of trench fever 3New bacterium discovered -- related to cause of trench fever 4In mice, drug protects against diabetes and atherosclerosis 2In mice, drug protects against diabetes and atherosclerosis 3In mice, drug protects against diabetes and atherosclerosis 4Ancient DNA traces the woolly mammoth's disappearance 2
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Anti-Cullin-1 Host: rabbit polyclonal Species Reactivity: human, mouse Applications: IHC(P), WB, IP Storage: 4C...
Request Info...
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
Biology Products: